The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients

Journal of Antimicrobial Chemotherapy

Volumn 47, Issue 4, 2001, Pages 421-429

  Joynt, G M ^a   Lipman, J ^b   Gomersall, C D ^a   Young, R J ^a   Wong, E L Y ^a   Gin, T ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; AZTREONAM; BILIRUBIN; CEFTRIAXONE; CEPHALOSPORIN; CREATININE; IMIPENEM; INOTROPIC AGENT; SEDATIVE AGENT; VANCOMYCIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICAL ILLNESS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION; HUMAN; INTENSIVE CARE; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; SEPSIS;

EID: 0035051828     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/47.4.421     Document Type: Article

References (41)

1. Pharmacokinetics
2. Multiple organ dysfunction score: A reliable'descriptor of a complex clinical outcome
3. Accumulation of midazolam after repeated dosage in patients receiving mechanical ventilation in an intensive care unit
4. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients
5. Aminoglycoside volume of distribution and illness severity in critically ill septic patients
6. The pharmacokinetics of amikacin in critically ill adult and paediatric patients: Comparison of once- versus twice-daily dosing regimens
7. Changes in vancomycin pharmacokinetics in critically ill infants
8. Pharmacokinetics of aztreonam in critically ill surgical patients
9. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia
10. Pharmacokinetics of antibiotics in critically ill patients
11. Clearance of ceftriaxone in critical care patients with acute renal failure
12. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
13. APACHE II: A severity of disease classification
14. Ion-pair high performance liquid chromatographic assay for ceftriaxone
15. Plasma protein binding of ceftriaxone
16. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults
17. Pharmacokinetics of ceftriaxone in humans
18. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics
19. The phenomenon of the acute phase response
20. Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life
21. The interaction of drugs and plasma proteins
22. The prognostic value of serial measurements of serum albumin concentration in patients admitted to an intensive care unit
23. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalised adults
24. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
25. Pharmacokinetic/pharmacodynamic parameters: Rationale for antimicrobial dosing of mice and men
26. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model
27. Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an vitro pharmacodynamic model versus the traditional time-kill method
28. Postantibiotic effects
29. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa
30. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries
31. Resistance to cephalosporins among gentamicin-resistant klebsiellae
32. Ceftriaxone-A new broad-spectrum semisynthetic cephalosporin. In vitro activity against Gram-negative bacilli sensitive and resistant to gentamicin
33. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use
34. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration
35. Is continuous infusion of β-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations
36. Continuous infusion of cefazolin is superior to intermittent dosing in decreasing infection after hemorrhagic shock
37. Increasing antibiotic dose decreases polymicrobial infection after hemorrhagic shock
38. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model
39. Continuous infusion ceftazidime in intensive care patients: A randomized controlled trial
40. Single-dose ceftriaxone kinetics in functionally anephric patients